Sarepta Shares Fall Amid Legal Turmoil and Analyst Downgrade

Sarepta Therapeutics shares are trading lower after Barclays downgraded the stock to 'Underweight' with a price target of $10, citing concerns over liquidity and regulatory issues following multiple patient deaths linked to its Elevidys therapy, which also led to multiple class-action lawsuits against the company.